PT1367057E - Epotilonas e e f - Google Patents

Epotilonas e e f Download PDF

Info

Publication number: PT1367057E
Authority: PT; Portugal
Prior art keywords: methanol; epothilone; resin; extract; reducing
Prior art date: 1996-11-18

Application number

PT03016552T

Other languages

English (en)

Inventor

Hofle Prof Dr Gerhard

Hans Reichenbach

Klaus Gerth

Heinrich Steinmetz

Original Assignee

Biotechnolog Forschung Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-18

Filing date

1997-11-18

Publication date

2008-12-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26031383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1367057(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-11-18 Application filed by Biotechnolog Forschung Gmbh filed Critical Biotechnolog Forschung Gmbh

2008-12-04 Publication of PT1367057E publication Critical patent/PT1367057E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biotechnology (AREA)
Environmental Sciences (AREA)
Dentistry (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Oncology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Silicon Polymers (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Epoxy Compounds (AREA)
Steroid Compounds (AREA)

PT03016552T 1996-11-18 1997-11-18 Epotilonas e e f PT1367057E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19647580		1996-11-18
DE19707506		1997-02-25

Publications (1)

Publication Number	Publication Date
PT1367057E true PT1367057E (pt)	2008-12-04

Family

ID=26031383

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT97951233T PT941227E (pt)	1996-11-18	1997-11-18	Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
PT03016552T PT1367057E (pt)	1996-11-18	1997-11-18	Epotilonas e e f

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT97951233T PT941227E (pt)	1996-11-18	1997-11-18	Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria

Country Status (23)

Country	Link
US (6)	US7067544B2 (pt)
EP (2)	EP1367057B1 (pt)
JP (1)	JP4274583B2 (pt)
KR (1)	KR100538095B1 (pt)
CN (2)	CN1196698C (pt)
AT (2)	ATE408612T1 (pt)
AU (1)	AU753546B2 (pt)
BR (1)	BR9713363B1 (pt)
CA (1)	CA2269118C (pt)
CY (1)	CY2542B1 (pt)
CZ (2)	CZ296164B6 (pt)
DE (2)	DE59712968D1 (pt)
DK (2)	DK0941227T5 (pt)
ES (2)	ES2221692T5 (pt)
HU (1)	HU229833B1 (pt)
IL (1)	IL129558A (pt)
NO (1)	NO319984B1 (pt)
NZ (1)	NZ335383A (pt)
PL (1)	PL193229B1 (pt)
PT (2)	PT941227E (pt)
RU (1)	RU2198173C2 (pt)
TW (1)	TW408119B (pt)
WO (1)	WO1998022461A1 (pt)

Families Citing this family (183)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1186606E (pt)	1995-11-17	2004-08-31	Biotechnolog Forschung Mbh Gbf	Derivados do epotilone sua preparacao e utilizacao
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
DK0941227T5 (da) *	1996-11-18	2009-10-05	Biotechnolog Forschung Gmbh	Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
CA2273083C (en) *	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en) *	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en)	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6320045B1 (en)	1997-12-04	2001-11-20	Bristol-Myers Squibb Company	Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en)	1998-04-21	2002-04-30	Bristol-Myers Squibb Company	12, 13-cyclopropane epothilone derivatives
US6498257B1 (en)	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
DE19820599A1 (de)	1998-05-08	1999-11-11	Biotechnolog Forschung Gmbh	Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
NZ508326A (en) *	1998-06-18	2003-10-31	Novartis Ag	A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
DE19826988A1 (de)	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
DE19846493A1 (de) *	1998-10-09	2000-04-13	Biotechnolog Forschung Gmbh	DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen
NZ511722A (en)	1998-11-20	2004-05-28	Kosan Biosciences Inc	Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en)	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
US6780620B1 (en)	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
EP1140928A4 (en) *	1998-12-23	2002-10-02	Bristol Myers Squibb Co	MICROBIAL CONVERSION METHOD FOR PRODUCING AN EPOTHILONE
US6596875B2 (en)	2000-02-07	2003-07-22	James David White	Method for synthesizing epothilones and epothilone analogs
KR100685336B1 (ko) *	1999-02-22	2007-02-23	게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프)	Ｃ-21 변형 에포틸론
US6291684B1 (en)	1999-03-29	2001-09-18	Bristol-Myers Squibb Company	Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
ES2391550T3 (es)	1999-04-15	2012-11-27	Bristol-Myers Squibb Company	Inhibidores cíclicos de la proteína tirosina quinasa
EP1229934B1 (en)	1999-10-01	2014-03-05	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6518421B1 (en) *	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
US6593115B2 (en)	2000-03-24	2003-07-15	Bristol-Myers Squibb Co.	Preparation of epothilone intermediates
US6998256B2 (en)	2000-04-28	2006-02-14	Kosan Biosciences, Inc.	Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
NZ546497A (en) *	2000-04-28	2008-04-30	Kosan Biosciences Inc	Production of polyketides
US6589968B2 (en)	2001-02-13	2003-07-08	Kosan Biosciences, Inc.	Epothilone compounds and methods for making and using the same
UA75365C2 (en)	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) *	2000-12-07	2001-01-24	Novartis Ag	Organic compounds
BRPI0206509B8 (pt)	2001-01-25	2021-05-25	R Pharm Us Operating Llc	processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
NZ526871A (en) *	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
MXPA03006485A (es)	2001-01-25	2003-09-22	Bristol Myers Squibb Co	Formulacion parenteral que contiene analogos de epotilona.
US6893859B2 (en)	2001-02-13	2005-05-17	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
EP1385529A4 (en)	2001-02-20	2007-05-09	Bristol Myers Squibb Co	TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES
MXPA03007423A (es)	2001-02-20	2003-11-18	Bristol Myers Squibb Co	Derivados de epotilona para tratamiento de tumores refractarios.
ATE434438T1 (de)	2001-02-27	2009-07-15	Novartis Pharma Gmbh	Kombination enthaltend einen inhibitor der signaltransduktion und ein epothilonderivat
NZ539204A (en)	2001-02-27	2005-12-23	Biotechnolog Forschung Gmbh	Degradation of epothilones and ethynyl substituted epothilones
IL157443A0 (en)	2001-03-14	2004-03-28	Bristol Myers Squibb Co	Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
EP1392664A4 (en)	2001-06-01	2005-01-26	Bristol Myers Squibb Co	EPOTHILONE DERIVATIVES
TWI315982B (en)	2001-07-19	2009-10-21	Novartis Ag	Combinations comprising epothilones and pharmaceutical uses thereof
DE10138347A1 (de) *	2001-08-03	2003-02-27	Schering Ag	Geschützte 3,5-Dihydroxy-2,2-dimethyl-valeronitrile für die Synthese von Epothilonen- und Derivaten und Verfahren zur Herstellung
TWI287986B (en) *	2001-12-13	2007-10-11	Novartis Ag	Use of Epothilones for the treatment of the carcinoid syndrome
US6884608B2 (en)	2001-12-26	2005-04-26	Bristol-Myers Squibb Company	Compositions and methods for hydroxylating epothilones
IL162595A0 (en)	2002-01-14	2005-11-20	Novartis Ag	Combinations comprising epothilones and antimetabolites
TW200303202A (en)	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
DK1483251T3 (da)	2002-03-12	2010-04-12	Bristol Myers Squibb Co	C3-cyano-epothilon-derivater
AU2003218107A1 (en)	2002-03-12	2003-09-29	Bristol-Myers Squibb Company	C12-cyano epothilone derivatives
TW200403994A (en)	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en)	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
WO2003105828A1 (en)	2002-06-14	2003-12-24	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ES2527052T3 (es) *	2002-07-29	2015-01-20	Optimer Pharmaceuticals, Inc.	Producción de tiacumicina
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
PT1506203E (pt) *	2002-08-23	2007-04-30	Sloan Kettering Inst Cancer	Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
CN1705662B (zh) *	2002-09-23	2011-07-06	布里斯托尔-迈尔斯斯奎布公司	埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构
CA2501717C (en) *	2002-10-15	2012-09-18	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Use of epothilone derivatives for the treatment of hyperparathyroidism
EP1567487A4 (en)	2002-11-15	2005-11-16	Bristol Myers Squibb Co	OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
CN100359014C (zh) *	2003-01-28	2008-01-02	北京华昊中天生物技术有限公司	一类新型埃坡霉素化合物及其制备方法和用途
US20050171167A1 (en)	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
PL2253614T3 (pl)	2004-04-07	2013-03-29	Novartis Ag	Inhibitory IAP
US10675326B2 (en)	2004-10-07	2020-06-09	The Board Of Trustees Of The University Of Illinois	Compositions comprising cupredoxins for treating cancer
MX2007005763A (es) *	2004-11-18	2007-07-20	Squibb Bristol Myers Co	Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma.
EP1824458A1 (en) *	2004-11-18	2007-08-29	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
EP1996550A2 (en)	2005-09-27	2008-12-03	Novartis AG	Carboxyamine compounds and their use in the treatment of hdac dependent diseases
NO346575B1 (no)	2005-11-21	2022-10-17	Novartis Ag	Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin i behandling av carcinoid eller småøyet celle cancer
GB0605120D0 (en)	2006-03-14	2006-04-26	Novartis Ag	Organic Compounds
US20110104664A1 (en)	2006-03-31	2011-05-05	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
RU2447891C2 (ru)	2006-04-05	2012-04-20	Новартис Аг	Комбинации терапевтических средств, предназначенные для лечения рака
CA2644143C (en)	2006-04-05	2013-10-01	Novartis Ag	Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
EP2026800A1 (en)	2006-05-09	2009-02-25	Novartis AG	Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
MX2009003185A (es)	2006-09-29	2009-04-03	Novartis Ag	Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
WO2008070672A2 (en)	2006-12-04	2008-06-12	The Board Of Trustees Of The University Of Illinois	Compositions and methods to treat cancer with cupredoxins and cpg rich dna
CN101668536A (zh)	2007-02-08	2010-03-10	伊利诺斯大学理事会	用铜氧还蛋白预防癌症的组合物和方法
CN101626758A (zh)	2007-02-15	2010-01-13	诺瓦提斯公司	用于治疗癌症的lbh589和其他治疗剂的组合
WO2009118292A1 (en)	2008-03-24	2009-10-01	Novartis Ag	Arylsulfonamide-based matrix metalloprotease inhibitors
EP2628726A1 (en)	2008-03-26	2013-08-21	Novartis AG	Hydroxamate-based inhibitors of deacetylases b
CN101362784A (zh) *	2008-10-06	2009-02-11	山东大学	埃博霉素苷类化合物和以其为活性成分的组合物及其应用
WO2010083617A1 (en)	2009-01-21	2010-07-29	Oncalis Ag	Pyrazolopyrimidines as protein kinase inhibitors
PT2391366E (pt)	2009-01-29	2013-02-05	Novartis Ag	Benzimidazoles substituídos para o tratamento de astrocitomas
JP5456891B2 (ja)	2009-06-26	2014-04-02	ノバルティスアーゲー	Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt)	2009-08-12	2016-05-17	Novartis Ag	compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
BR112012008061A2 (pt)	2009-08-20	2016-03-01	Novartis Ag	compostos de oxima heterocíclica
IN2012DN01693A (pt)	2009-08-26	2015-06-05	Novartis Ag
BR112012010519A2 (pt)	2009-11-04	2017-12-05	Novartis Ag	derivados de sulfonamida heterocíclicos
ES2484171T3 (es)	2009-12-08	2014-08-11	Novartis Ag	Derivados de sulfonamidas heterocíclicas
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
CU24130B1 (es)	2009-12-22	2015-09-29	Novartis Ag	Isoquinolinonas y quinazolinonas sustituidas
EP2571525A4 (en)	2010-05-18	2016-04-27	Cerulean Pharma Inc	Compositions and methods for treating autoimmune and other diseases
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
EP2627648A1 (en)	2010-09-16	2013-08-21	Novartis AG	17aHYDROXYLASE/C17,20-LYASE INHIBITORS
EP2665493B1 (en)	2011-01-20	2018-03-21	Board Of Regents, The University Of Texas System	Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
EP2673277A1 (en)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
ES2656218T3 (es)	2011-04-28	2018-02-26	Novartis Ag	Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa
IN2014DN00123A (pt)	2011-06-09	2015-05-22	Novartis Ag
KR102087854B1 (ko)	2011-06-10	2020-03-12	메르사나 테라퓨틱스, 인코포레이티드	단백질-중합체-약물 접합체
EP2721007B1 (en)	2011-06-20	2015-04-29	Novartis AG	Cyclohexyl isoquinolinone compounds
US8859535B2 (en)	2011-06-20	2014-10-14	Novartis Ag	Hydroxy substituted isoquinolinone derivatives
KR20140025530A (ko)	2011-06-27	2014-03-04	노파르티스 아게	테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
EP2755976B1 (en)	2011-09-15	2018-07-18	Novartis AG	6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US8969341B2 (en)	2011-11-29	2015-03-03	Novartis Ag	Pyrazolopyrrolidine compounds
US20150148377A1 (en)	2011-12-22	2015-05-28	Novartis Ag	Quinoline Derivatives
PT2794600T (pt)	2011-12-22	2018-03-13	Novartis Ag	Derivados de 2,3-di-hidro-benzo[1,4]oxazina e compostos relacionados como inibidores de fosfoinositídeo-3-cinase (pi3k) para o tratamento de, por exemplo, artrite reumatoide
JP2015503519A (ja)	2011-12-23	2015-02-02	ノバルティスアーゲー	Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
CA2859867A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
CN104136428A (zh)	2011-12-23	2014-11-05	诺华股份有限公司	用于抑制bcl2与结合配偶体相互作用的化合物
JP2015503518A (ja)	2011-12-23	2015-02-02	ノバルティスアーゲー	Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
EA201491268A1 (ru)	2011-12-23	2014-11-28	Новартис Аг	Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
KR101372563B1 (ko)	2011-12-26	2014-03-14	주식회사 삼양바이오팜	에포틸론 함유물질로부터 에포틸론 ａ와 ｂ의 추출 및 정제 방법
UY34591A (es)	2012-01-26	2013-09-02	Novartis Ag	Compuestos de imidazopirrolidinona
SG11201407152XA (en)	2012-05-15	2014-11-27	Novartis Ag	Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
EA201492007A1 (ru)	2012-05-15	2015-03-31	Новартис Аг	Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
BR112014027584B1 (pt)	2012-05-15	2023-01-24	Novartis Ag	Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
CN104379574B (zh)	2012-05-15	2017-03-01	诺华股份有限公司	用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
US9365576B2 (en)	2012-05-24	2016-06-14	Novartis Ag	Pyrrolopyrrolidinone compounds
JP6427097B2 (ja)	2012-06-15	2018-11-21	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	癌を処置するための組成物および該組成物を製造するための方法
PT2903968T (pt)	2012-10-02	2017-03-13	Gilead Sciences Inc	Inibidores de desmetilases de histonas
US9725477B2 (en)	2012-11-17	2017-08-08	Beijing Fswelcome Technology Development Co., Ltd	Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
CA2892863C (en)	2012-12-10	2022-03-15	Mersana Therapeutics, Inc.	Polymeric scaffold based on phf for targeted drug delivery
WO2014093640A1 (en)	2012-12-12	2014-06-19	Mersana Therapeutics,Inc.	Hydroxy-polmer-drug-protein conjugates
JO3464B1 (ar)	2013-01-15	2020-07-05	Astellas Pharma Europe Ltd	التركيبات الخاصة بمركبات التياكوميسين
US9556180B2 (en)	2013-01-22	2017-01-31	Novartis Ag	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
US9403827B2 (en)	2013-01-22	2016-08-02	Novartis Ag	Substituted purinone compounds
WO2014128612A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Quinazolin-4-one derivatives
EP2961736B1 (en)	2013-02-27	2018-04-11	Gilead Sciences, Inc.	Inhibitors of histone demethylases
US20150018376A1 (en)	2013-05-17	2015-01-15	Novartis Ag	Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
MX2015017120A (es)	2013-06-11	2016-10-05	Bayer Pharma AG	Combinaciones para el tratamiento de cancer que comprende un inhibidor de la quinasa mps-1 y un inhibidor de la mitosis.
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
WO2015022663A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
WO2015022664A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
US9227969B2 (en)	2013-08-14	2016-01-05	Novartis Ag	Compounds and compositions as inhibitors of MEK
JP6494634B2 (ja)	2013-09-22	2019-04-03	キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒＳｃｉｅｎｃｅｓ，Ｌｌｃ	置換されているアミノピリミジン化合物および使用方法
US10316080B2 (en)	2013-10-11	2019-06-11	Asana Biosciences, Llc	Protein-polymer-drug conjugates
KR102087850B1 (ko)	2013-10-11	2020-03-12	메르사나 테라퓨틱스, 인코포레이티드	단백질-고분자-약물 접합체
EP3312164B1 (en)	2014-03-28	2020-12-09	Calitor Sciences, LLC	Substituted heteroaryl compounds and methods of use
EP3126345A1 (en)	2014-03-31	2017-02-08	Gilead Sciences, Inc.	Inhibitors of histone demethylases
US10426753B2 (en)	2014-04-03	2019-10-01	Invictus Oncology Pvt. Ltd.	Supramolecular combinatorial therapeutics
EA201790154A1 (ru)	2014-08-27	2017-08-31	Джилид Сайэнс, Инк.	Соединения и способы для ингибирования гистоновых деметилаз
JP2018527362A (ja)	2015-09-11	2018-09-20	サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅＬａｋｅＰｈａｒｍａＣｏ．，Ｌｔｄ．	置換されたヘテロアリール化合物および使用方法
EP3474901B1 (en)	2016-06-27	2025-08-06	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
JP7320458B2 (ja)	2017-06-22	2023-08-03	メルサナセラピューティクスインコーポレイテッド	薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
US10683297B2 (en)	2017-11-19	2020-06-16	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
US10751339B2 (en)	2018-01-20	2020-08-25	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine compounds and methods of use
CA3099421C (en)	2018-05-04	2025-05-06	Tagworks Pharmaceuticals B.V.	COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY
US20210299286A1 (en)	2018-05-04	2021-09-30	Tagworks Pharmaceuticals B.V.	Tetrazines for high click conjugation yield in vivo and high click release yield
CN113365664A (zh)	2018-10-29	2021-09-07	梅尔莎纳医疗公司	具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
FR3087650B1 (fr)	2018-10-31	2021-01-29	Bio Even	Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
DK3983363T3 (da)	2019-06-17	2024-06-24	Tagworks Pharmaceuticals B V	Forbindelser til hurtig og effektiv klikfrigivelse
IL289094A (en)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	Tetrazines for increasing the speed and yield of the "click release" reaction
WO2023031445A2 (en)	2021-09-06	2023-03-09	Veraxa Biotech Gmbh	Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
DK4186529T3 (da)	2021-11-25	2025-08-25	Veraxa Biotech Gmbh	Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
CA3238627A1 (en)	2021-11-25	2023-06-01	Christine Kohler	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
EP4444356A1 (en)	2021-12-08	2024-10-16	European Molecular Biology Laboratory	Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
IL314951B2 (en)	2022-02-15	2025-07-01	Tagworks Pharmaceuticals B V	Masked il12 protein
EP4554624A1 (en)	2022-07-15	2025-05-21	Pheon Therapeutics Ltd	Antibody-drug conjugates
EP4602023A1 (en)	2022-10-12	2025-08-20	Tagworks Pharmaceuticals B.V.	Strained bicyclononenes
WO2024153789A1 (en)	2023-01-20	2024-07-25	Basf Se	Stabilized biopolymer composition, their manufacture and use
KR20250169530A (ko)	2023-03-10	2025-12-03	태그웍스 파마슈티컬스 비.브이.	개선된 t-링커를 갖는 트랜스-사이클로옥텐
AU2024300552A1 (en)	2023-07-27	2026-01-29	Veraxa Biotech Gmbh	Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
EP4512395A1 (en)	2023-08-21	2025-02-26	Bio Even	Composition comprising flavin adenine dinucleotide (fad), l-gsh, atp and myristic acid, alone or with a drug
WO2025056807A1 (en)	2023-09-15	2025-03-20	Basf Se	Stabilized biopolymer composition, their manufacture and use
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025174248A1 (en)	2024-02-16	2025-08-21	Tagworks Pharmaceuticals B.V.	Trans-cyclooctenes with "or gate" release

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0358606A3 (de)	1988-09-09	1990-10-31	Gesellschaft für Biotechnologische Forschung mbH (GBF)	Mikrobiologisches Verfahren zur Herstellung agrarchemisch verwendbarer mikrobizider makrozyklischer Lactonderivate
GB8909737D0 (en) *	1989-04-27	1989-06-14	Shell Int Research	Thiazole derivatives
DE4138042C2 (de) *	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
ZA941544B (en) *	1993-03-05	1994-10-31	Hexal Pharma Gmbh	Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same.
US6252094B1 (en) *	1994-01-11	2001-06-26	The Scripps Research Institute	Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) *	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
PT1186606E (pt)	1995-11-17	2004-08-31	Biotechnolog Forschung Mbh Gbf	Derivados do epotilone sua preparacao e utilizacao
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de)	1996-08-30	1997-10-23	Schering Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
NZ334821A (en) *	1996-08-30	2000-12-22	Novartis Ag	Method for producing epothilones
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
DK0941227T5 (da)	1996-11-18	2009-10-05	Biotechnolog Forschung Gmbh	Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
CA2273083C (en) *	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) *	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6441186B1 (en) *	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en)	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
CN1128803C (zh)	1997-02-25	2003-11-26	生物技术研究有限公司(Gbf)	环氧噻嗪酮b－n－氧化物及其制备方法
US5828449A (en)	1997-02-26	1998-10-27	Acuity Imaging, Llc	Ring illumination reflective elements on a generally planar surface
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de)	1997-04-18	2002-10-09	Studiengesellschaft Kohle mbH	Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) *	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
PT1001951E (pt)	1997-07-16	2003-02-28	Schering Ag	Derivados de tiazolo, processo para a sua preparacao e utilizacao
US7407975B2 (en)	1997-08-09	2008-08-05	Bayer Schering Pharma Ag	Epothilone derivatives, method for producing same and their pharmaceutical use
AU753519B2 (en)	1998-02-05	2002-10-17	Novartis Ag	Compositions containing organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en)	1998-02-25	2012-05-29	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE19826988A1 (de) *	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
AU5036999A (en)	1998-06-30	2000-01-17	Schering Aktiengesellschaft	Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
NZ511722A (en)	1998-11-20	2004-05-28	Kosan Biosciences Inc	Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) *	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
BR9916833A (pt)	1998-12-22	2001-09-25	Novartis Ag	Derivados de epotilona e seu uso como agentes antitumor
US6780620B1 (en) *	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) *	2000-02-07	2003-07-22	James David White	Method for synthesizing epothilones and epothilone analogs
DE50014587D1 (de)	1999-02-18	2007-10-04	Bayer Schering Pharma Ag	16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
KR100685336B1 (ko) *	1999-02-22	2007-02-23	게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프)	Ｃ-21 변형 에포틸론
US6211412B1 (en) *	1999-03-29	2001-04-03	The University Of Kansas	Synthesis of epothilones
AR023792A1 (es)	1999-04-30	2002-09-04	Bayer Schering Pharma Ag	Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
TWI310684B (en) *	2000-03-27	2009-06-11	Bristol Myers Squibb Co	Synergistic pharmaceutical kits for treating cancer
US6589968B2 (en) *	2001-02-13	2003-07-08	Kosan Biosciences, Inc.	Epothilone compounds and methods for making and using the same
US6489314B1 (en) *	2001-04-03	2002-12-03	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
US6906188B2 (en) *	2001-04-30	2005-06-14	State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Method for synthesizing epothilones and epothilone analogs
WO2003029195A1 (en) *	2001-09-28	2003-04-10	Sumika Fine Chemicals Co., Ltd.	Intermediates for epothilone derivative and process for producing these
US6884608B2 (en) *	2001-12-26	2005-04-26	Bristol-Myers Squibb Company	Compositions and methods for hydroxylating epothilones
TW200303202A (en)	2002-02-15	2003-09-01	Bristol Myers Squibb Co	Method of preparation of 21-amino epothilone derivatives
US6921769B2 (en) *	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
CN1705662B (zh)	2002-09-23	2011-07-06	布里斯托尔-迈尔斯斯奎布公司	埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构

1997
- 1997-11-18 DK DK97951233T patent/DK0941227T5/da active
- 1997-11-18 CN CNB971998140A patent/CN1196698C/zh not_active Expired - Lifetime
- 1997-11-18 IL IL12955897A patent/IL129558A/en not_active IP Right Cessation
- 1997-11-18 HU HU0000497A patent/HU229833B1/hu unknown
- 1997-11-18 ES ES97951233T patent/ES2221692T5/es not_active Expired - Lifetime
- 1997-11-18 EP EP03016552A patent/EP1367057B1/de not_active Expired - Lifetime
- 1997-11-18 PT PT97951233T patent/PT941227E/pt unknown
- 1997-11-18 AT AT03016552T patent/ATE408612T1/de active
- 1997-11-18 BR BRPI9713363-9A patent/BR9713363B1/pt not_active IP Right Cessation
- 1997-11-18 AT AT97951233T patent/ATE267197T1/de active
- 1997-11-18 JP JP52320898A patent/JP4274583B2/ja not_active Expired - Lifetime
- 1997-11-18 ES ES03016552T patent/ES2312695T3/es not_active Expired - Lifetime
- 1997-11-18 DK DK03016552T patent/DK1367057T3/da active
- 1997-11-18 RU RU99113031/04A patent/RU2198173C2/ru active
- 1997-11-18 AU AU54837/98A patent/AU753546B2/en not_active Expired
- 1997-11-18 CA CA2269118A patent/CA2269118C/en not_active Expired - Lifetime
- 1997-11-18 CZ CZ0175099A patent/CZ296164B6/cs not_active IP Right Cessation
- 1997-11-18 NZ NZ335383A patent/NZ335383A/xx not_active IP Right Cessation
- 1997-11-18 PT PT03016552T patent/PT1367057E/pt unknown
- 1997-11-18 KR KR10-1999-7004302A patent/KR100538095B1/ko not_active Expired - Lifetime
- 1997-11-18 CN CNB2005100062827A patent/CN100344627C/zh not_active Expired - Lifetime
- 1997-11-18 EP EP97951233A patent/EP0941227B2/de not_active Expired - Lifetime
- 1997-11-18 DE DE59712968T patent/DE59712968D1/de not_active Expired - Lifetime
- 1997-11-18 WO PCT/EP1997/006442 patent/WO1998022461A1/de not_active Ceased
- 1997-11-18 PL PL333435A patent/PL193229B1/pl unknown
- 1997-11-18 CZ CZ20041118A patent/CZ303422B6/cs not_active IP Right Cessation
- 1997-11-18 DE DE59711647T patent/DE59711647D1/de not_active Expired - Lifetime
1998
- 1998-01-21 TW TW086117334A patent/TW408119B/zh not_active IP Right Cessation
1999
- 1999-05-14 NO NO19992338A patent/NO319984B1/no not_active IP Right Cessation
2004
- 2004-11-12 US US10/988,328 patent/US7067544B2/en not_active Expired - Fee Related
2005
- 2005-10-26 CY CY0500058A patent/CY2542B1/xx unknown
2006
- 2006-04-27 US US11/412,536 patent/US20060264482A1/en not_active Abandoned
2008
- 2008-04-28 US US12/110,781 patent/US20080293784A1/en not_active Abandoned
2009
- 2009-03-24 US US12/409,823 patent/US7846952B2/en not_active Expired - Fee Related
- 2009-05-01 US US12/434,078 patent/US7759375B2/en not_active Expired - Fee Related
2010
- 2010-12-06 US US12/961,447 patent/US8076490B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2221692T5 (es)	2009-12-14
EP0941227B2 (de)	2009-10-14
IL129558A (en)	2001-10-31
EP0941227B1 (de)	2004-05-19
US20110136185A1 (en)	2011-06-09
PT941227E (pt)	2004-08-31
ES2221692T4 (es)	2005-10-01
CZ296164B6 (cs)	2006-01-11
DE59712968D1 (de)	2008-10-30
KR20000053308A (ko)	2000-08-25
HU229833B1 (en)	2014-09-29
ATE267197T1 (de)	2004-06-15
CN1680370A (zh)	2005-10-12
HUP0000497A2 (hu)	2000-06-28
DE59711647D1 (de)	2004-06-24
PL333435A1 (en)	1999-12-06
CA2269118A1 (en)	1998-05-28
ES2312695T3 (es)	2009-03-01
CN1196698C (zh)	2005-04-13
US20050090535A1 (en)	2005-04-28
US20090247592A1 (en)	2009-10-01
JP4274583B2 (ja)	2009-06-10
BR9713363A (pt)	2000-01-25
EP0941227A1 (de)	1999-09-15
NO992338D0 (no)	1999-05-14
US7846952B2 (en)	2010-12-07
US20090270466A1 (en)	2009-10-29
NO319984B1 (no)	2005-10-10
CY2542B1 (en)	2006-06-28
CZ303422B6 (cs)	2012-09-05
US8076490B2 (en)	2011-12-13
RU2198173C2 (ru)	2003-02-10
DK0941227T4 (da)	2008-05-19
NZ335383A (en)	2000-10-27
US7067544B2 (en)	2006-06-27
PL193229B1 (pl)	2007-01-31
CA2269118C (en)	2012-05-29
EP1367057A1 (de)	2003-12-03
CN1237970A (zh)	1999-12-08
WO1998022461A1 (de)	1998-05-28
AU5483798A (en)	1998-06-10
TW408119B (en)	2000-10-11
HK1022314A1 (en)	2000-08-04
EP0941227B9 (de)	2005-05-04
AU753546B2 (en)	2002-10-24
DK1367057T3 (da)	2009-01-19
US20080293784A1 (en)	2008-11-27
ATE408612T1 (de)	2008-10-15
JP2001504474A (ja)	2001-04-03
HUP0000497A3 (en)	2001-10-29
IL129558A0 (en)	2000-02-29
CZ175099A3 (cs)	1999-09-15
HK1083832A1 (zh)	2006-07-14
NO992338L (no)	1999-05-14
US7759375B2 (en)	2010-07-20
DK0941227T5 (da)	2009-10-05
ES2221692T3 (es)	2005-01-01
EP1367057B1 (de)	2008-09-17
BR9713363B1 (pt)	2011-02-08
CN100344627C (zh)	2007-10-24
DK0941227T3 (da)	2004-06-28
US20060264482A1 (en)	2006-11-23
KR100538095B1 (ko)	2005-12-21

Publication	Publication Date	Title
PT1367057E (pt)	2008-12-04	Epotilonas e e f
DK0643689T3 (da)	1999-08-30	Forbedret fremgangsmåde til syntese af (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoat
DK0553213T3 (da)	1995-07-17	Fremgangsmåde til fremstilling af (4R-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxan- 4-acetat
NO953762L (no)	1995-09-25	Innrettet fiberarmert panel for deler av tre
WO2004092885A3 (en)	2005-05-06	User interface for controlling a whirlpool tub
GR3022289T3 (en)	1997-04-30	Method for treating alcoholism with nalmefene
WO1999065913A3 (de)	2000-04-20	Epothilon-nebenkomponenten
EP0745610A3 (en)	1996-12-18	Process for preparing anti-obesity protein
AU7436494A (en)	1995-05-04	Protein isolate having an increased level of isoflavone compound and process for producing the same
ES2160895T3 (es)	2001-11-16	Produccion de un suero proteinico vegetal enriquecido con isoflavonas agluconicas.
IT1250692B (it)	1995-04-21	Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi.
Mercer et al.	1987	Echinococcus granulosus: occurrence of ecdysteroids in protoscoleces and hydatid cyst fluid
AU1438992A (en)	1992-11-17	Water extraction components produced by adhesive bonds, process for their manufacture and their use
Choi et al.	1997	Recovery of isoflavones from soybean cooking water produced during soymilk manufacturing process
WO1997004101A3 (de)	1997-04-03	Enzym geeignet zur oxidation von cyclitolen und ihren derivaten
WO1997022769A3 (de)	1997-10-23	Fuss für einen zaunpfahl oder für eine strebe an einem zaunpfahl
AU694675B2 (en)	1998-07-23	Process for the isomerization of olefins
IT1245863B (it)	1994-10-25	Processo per separare materiale plastico eterogeneo in frazioni omogenee
ES1030366U (es)	1995-08-01	Rebosadero perfeccionado, para bañeras y similares.
AU2697397A (en)	1997-11-12	Novel acetals of hydroxy carboxylic acids, derivatives thereof and process for the preparation thereof
EP0975090A3 (de)	2000-11-08	Begrenzerschaltung für HF-Signale
ES1015922U (es)	1991-10-01	Pieza de union para tazas de retrete.